687 related articles for article (PubMed ID: 16897817)
1. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
Huang WF; Hsiao FY; Wen YW; Tsai YW
Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
[TBL] [Abstract][Full Text] [Related]
3. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
[TBL] [Abstract][Full Text] [Related]
8. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
10. Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.
Goldstein JL; Zhao SZ; Burke TA; Palmer R; von Allmen H; Henderson SC
Am J Gastroenterol; 2003 Dec; 98(12):2627-34. PubMed ID: 14687808
[TBL] [Abstract][Full Text] [Related]
11. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
[TBL] [Abstract][Full Text] [Related]
13. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
14. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
15. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
Becker MC; Wang TH; Wisniewski L; Wolski K; Libby P; Lüscher TF; Borer JS; Mascette AM; Husni ME; Solomon DH; Graham DY; Yeomans ND; Krum H; Ruschitzka F; Lincoff AM; Nissen SE;
Am Heart J; 2009 Apr; 157(4):606-12. PubMed ID: 19332185
[TBL] [Abstract][Full Text] [Related]
16. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
[TBL] [Abstract][Full Text] [Related]
18. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
Patterson MK; Castellsague J; Walker AM
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
[TBL] [Abstract][Full Text] [Related]
20. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
